Chiesi Group, an international research-focused biopharmaceutical corporation and certified B Corp, has officially finalized its corporate acquisition of KalVista Pharmaceuticals Inc. for an aggregate transaction value of approximately $1.9 billion. Following the structural integration, KalVista will operate as a subsidiary asset and directly drive the scaling of Chiesi’s dedicated Rare Diseases business unit, which commands institutional responsibility for the research, development, and commercialization of therapeutics engineered for rare and ultra-rare medical conditions.
The documented transfer of the proprietary molecule EKTERLY, expanded pediatric clinical roadmaps, and macro corporate synergy strategies feature:
-
Exclusive Ownership of the On-Demand Oral HAE Therapy EKTERLY:
-
Product Stature: Upon completion of the financial consolidation, Chiesi assumed full asset ownership of EKTERLY (sebetralstat). The small molecule functions as the first and only oral, on-demand medical treatment authorized for the management of hereditary angioedema (HAE) attacks in adult and adolescent cohorts aged 12 years and older.
-
Global Regulatory Standings: EKTERLY retains active commercial marketing authorizations across major international jurisdictions, including the United States, the United Kingdom, the European Union, and Japan. Concurrently, multiple supplementary regulatory files and marketing applications are under active review by healthcare watchdogs across key global markets.
-
-
Clinical Expansion Timelines for Pediatric Cohorts:
-
Supplementing existing adult commercial indications, Chiesi and KalVista are actively steering continuous, ongoing clinical evaluation protocols for the molecule.
-
The active research track is engineered to validate the efficacy and safety profiles of sebetralstat for treating acute HAE attacks in pediatric patients spanning the 2 to 11 age demographic.
-
-
Strategic Rationale and Macro Operational Synergy:
-
Jean-Marc Bellemin, Chiesi Group’s CFO and Interim Group CEO, asserted that the acquisition directly anchors the group’s long-term strategy to accelerate therapeutic impact within the rare disease landscape. The consolidation unites science, clinical innovation, and biopharma expertise to address therapeutic spaces presenting the highest unmet medical needs.
-
The baseline alliance bridges KalVista’s proven molecular drug discovery and clinical development pipelines with Chiesi’s established global commercial footprint and localized operational excellence, enabling the joint enterprise to deliver innovative medical solutions to patient populations at a significantly greater macro scale.
-